Chronic Hepatitis B Virus Infection Pipeline Insight, Clinical Trials Analysis, FDA Approvals 2023 | Major Companies – Vedanta Biosciences, Gilead Sciences, Arbutus Biopharma, Vir Biotechnology, and Ot

May 18 20:06 2023
Chronic Hepatitis B Virus Infection Pipeline Insight, Clinical Trials Analysis, FDA Approvals 2023 | Major Companies - Vedanta Biosciences, Gilead Sciences, Arbutus Biopharma, Vir Biotechnology, and Ot

DelveInsight’s, “Chronic Hepatitis B Virus Pipeline Insight 2023” report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in the Chronic Hepatitis B Virus pipeline landscape. It covers the Chronic Hepatitis B Virus pipeline drug profiles, including Chronic Hepatitis B Virus clinical trials and nonclinical stage products. It also covers the Chronic Hepatitis B Virus therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Chronic Hepatitis B Virus Pipeline Report

 

  • DelveInsight’s Chronic Hepatitis B Virus Infection Pipeline report depicts a robust space with 50+ active players working to develop 55+ pipeline therapies for Chronic Hepatitis B Virus Infection treatment.

 

  • The leading Chronic Hepatitis B Virus Infection Companies include Vedanta Biosciences, Gilead Sciences, Dong-A ST Co, Assembly Biosciences, Arbutus Biopharma, Vir Biotechnology, Antios Therapeutics, Ascletis Pharmaceuticals, Shanghai HEP Pharmaceutical, Romark Laboratories, Qilu Pharmaceutical, Golden Biotechnology, Sunshine Lake Pharma, Ascentage Pharma, GlaxoSmithKline, Janssen Sciences, Henlix, Enyo Pharma, Tasly Tianjin Biopharmaceutical, Brii Biosciences, Vaxine Pty Ltd, Vaccitech limited, Zhejiang Palo Alto Pharmaceuticals, Suzhou Ribo Life Science, PharmaEssentia, Nucorion Pharmaceuticals, Jiangsu HengRui Medicine, Enanta Pharmaceuticals, Chong Kun Dang Pharmaceutical, Guangzhou Lupeng Pharmaceutical, VenatoRx Pharmaceuticals, Zhimeng Biopharm, and others. 

 

  • Promising Chronic Hepatitis B Virus Infection Pipeline therapies include Entecavir, telbivudine, lamivudine, Bepirovirsen, RG6346, and others

 

  • The Chronic Hepatitis B Virus Infection companies and academics are working to assess challenges and seek opportunities that could influence in Chronic Hepatitis B Virus Infection R&D. The Chronic Hepatitis B Virus Infection therapies under development are focused on novel approaches to treat/improve in Chronic Hepatitis B Virus Infection.

 

Request a sample and discover the recent breakthroughs happening in the Chronic Hepatitis B Virus Infection Pipeline landscape @ Chronic Hepatitis B Virus Infection Pipeline Outlook

 

Chronic Hepatitis B Virus Infection Overview

Hepatitis B viral infection is a serious global healthcare problem. It is a potentially life-threatening liver infection caused by the hepatitis B virus (HBV). It is often transmitted via body fluids like blood, semen, and vaginal secretions. The majority (more than 95%) of immunocompetent adults infected with HBV can clear the infection spontaneously. Patients can present with acute symptomatic disease or have an asymptomatic infection that is identified during screening for HBV.

 

Recent Developmental Activities in the Chronic Hepatitis B Virus Infection Treatment Landscape

 

  • In November, 2022,  The U.S. Food and Drug Administration (FDA) has authorised the supplemental new drug application (sNDA) for Vemlidy® (tenofovir alafenamide) 25 mg tablets as a once-daily treatment for chronic hepatitis B virus (HBV) infection in paediatric patients 12 years of age and older with compensated liver disease, according to a press release from Gilead Sciences, Inc. (Nasdaq: GILD).

 

For further information, refer to the detailed Chronic Hepatitis B Virus Infection Drugs Launch, Chronic Hepatitis B Virus Infection Developmental Activities, and Chronic Hepatitis B Virus Infection News, click here for Chronic Hepatitis B Virus Infection Ongoing Clinical Trial Analysis

 

Chronic Hepatitis B Virus Infection Emerging Drugs Profile

 

  • Pradefovir: Ligand Pharmaceuticals

Pradefovir is an oral liver-targeting prodrug of the HBV DNA polymerase/reverse transcriptase inhibitor adefovir, for the potential treatment of hepatitis B virus (HBV) infection. The drug is developing using Ligand’s HepDirect technology. Currently the product is in Phase III stage of development for the treatment of Chronic Hepatitis B.

 

  • RG6346: Dicerna Pharmaceuticals

RG6346 is an investigational GalXC™ RNAi therapeutic candidate in development in collaboration with Roche for the treatment of chronic HBV infection. RG6346 is designed to employ RNA interference to selectively knock down specific genes involved in the creation of HBV messenger RNA (mRNA) and the entry of the virus into liver cells. Preclinical data have demonstrated greater than 99.9% reduction in circulating HBsAg, as observed in mouse models of HBV infection. Unlike current therapies that typically provide long-term suppression of the virus, RG6346 has the potential to provide a functional cure for patients living with chronic HBV. Dicerna is currently conducting a Phase II trial of RG6346 in adult patients with chronic HBV infection.

 

Chronic Hepatitis B Virus Infection Pipeline Therapeutics Assessment

There are approx. 50+ key companies which are developing the therapies for Chronic Hepatitis B Virus Infection. The companies which have their Chronic Hepatitis B Virus Infection drug candidates in the most advanced stage, i.e. Phase III include, Ligand Pharmaceuticals.

 

Find out more about the Chronic Hepatitis B Virus Infection Pipeline Segmentation, Therapeutics Assessment, and Chronic Hepatitis B Virus Infection Emerging Drugs @ Chronic Hepatitis B Virus Infection Treatment Landscape

 

Scope of the Chronic Hepatitis B Virus Infection Pipeline Report

 

  • Coverage- Global

 

  • Chronic Hepatitis B Virus Infection Companies- Vedanta Biosciences, Gilead Sciences, Dong-A ST Co, Assembly Biosciences, Arbutus Biopharma, Vir Biotechnology, Antios Therapeutics, Ascletis Pharmaceuticals, Shanghai HEP Pharmaceutical, Romark Laboratories, Qilu Pharmaceutical, Golden Biotechnology, Sunshine Lake Pharma, Ascentage Pharma, GlaxoSmithKline, Janssen Sciences, Henlix, Enyo Pharma, Tasly Tianjin Biopharmaceutical, Brii Biosciences, Vaxine Pty Ltd, Vaccitech limited, Zhejiang Palo Alto Pharmaceuticals, Suzhou Ribo Life Science, PharmaEssentia, Nucorion Pharmaceuticals, Jiangsu HengRui Medicine, Enanta Pharmaceuticals, Chong Kun Dang Pharmaceutical, Guangzhou Lupeng Pharmaceutical, VenatoRx Pharmaceuticals, Zhimeng Biopharm, and others

 

  • Chronic Hepatitis B Virus Infection Pipeline therapies- Entecavir, telbivudine, lamivudine, Bepirovirsen, RG6346, and others.

 

  • Chronic Hepatitis B Virus Infection Pipeline Segmentation: Product Type, Molecule Type, Route of Administration

 

Dive deep into rich insights for drugs for Chronic Hepatitis B Virus Infection Pipeline Companies and Therapies, click here @ Chronic Hepatitis B Virus Infection Unmet Needs and Analyst Views

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Chronic Hepatitis B Virus Infection: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Chronic Hepatitis B Virus Infection – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Pradefovir: Ligand Pharmaceuticals
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. RG6346: Dicerna Pharmaceuticals
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I/II)
  14. Drug name: Company name
  15. Drug profiles in the detailed report…..
  16. Early Stage Products (Phase I)
  17. VIR-3434: Vir Biotechnology
  18. Drug profiles in the detailed report…..
  19. Preclinical Stage Products
  20. SBT8230: Silverback Therapeutics
  21. Drug profiles in the detailed report…..
  22. Inactive Products
  23. Chronic Hepatitis B Virus Infection Key Companies
  24. Chronic Hepatitis B Virus Infection Key Products
  25. Chronic Hepatitis B Virus Infection – Unmet Needs
  26. Chronic Hepatitis B Virus Infection – Market Drivers and Barriers
  27. Chronic Hepatitis B Virus Infection – Future Perspectives and Conclusion
  28. Chronic Hepatitis B Virus Infection Analyst Views
  29. Chronic Hepatitis B Virus Infection Key Companies
  30. Appendix

 

Got Queries? Find out the related information on Chronic Hepatitis B Virus Infection Mergers and acquisitions, Chronic Hepatitis B Virus Infection Licensing Activities @ Chronic Hepatitis B Virus Infection Recent Trends, and Future Perspectives

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/